Crizanlizumab for anemia, sickle cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Jul 2022: Trial registered, NCT05469828

The trials

NCT05469828: Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia

State
Not started
Phase
Phase 1 and Phase 2
People
30 planned
Started
1 Jul 2024
Primary completion
1 Jul 2028
Arms
treatment
Results
None posted
  1. 22 Jul 2022: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.